OBJECTIVE: To investigate the diagnosis value of fibro-optic-bronchoscope combined with tumor maker determination to lung cancer. METHODS: By fibro-optic bronchoscope (FB) and electrochemiluminescence (ECL) examinations, 98 cases with lung cancer and 88 cases with benign lung disease were studied for calculating the detectable sensitivity and specificity to lung cancer, then further for evaluating the clinical value of FB examination combined with detection of tumor marker in serum/pleural fluid of patients with lung cancer. Results In patients with lung cancer, the serum levels of CEA, CA125 and CYFRA21-1 were (46.34 +/- 18.28) ng/mL, (83.34 +/- 33.26) U/mL and (25.67 +/- 10.32) ng/mL respectively, which were higher than those in patients with benign lung diseases. The serum levels of above three tumor markers in patients with lung cancer all were significantly higher than those in patients with benign lung diseases (P < 0.05). In the 36 specimens of pleural fluid, three tumor markers were higher than those in the corresponding serum samples. The detectable sensitivity of each tumor marker in pleural fluid was higher than that in serum. The sensitivity, specificity and overall accuracy of CEA in lung cancer were 37.5%, 87.5% and 63.6% respectively, of CA125 were 67.7%, 40.9% and 54.9%; of CYFRA21-1 were 56.3%, 81.8% and 68.5%; of FB were 60.4%, 100.0% and 79.4% respectively. The sensitivity, specificity or overall accuracy of fibro-optic bronchoscope combined with tumor marker (TM) examination to diagnosis of lung cancer was 90.6%, 92.0% or 91.3% respectively. CONCLUSION: The FB examination is valuable in diagnosing lung cancer, and by combined with TM determination, can further improve the accuracy to diagnosis of lung cancer.
OBJECTIVE: To investigate the diagnosis value of fibro-optic-bronchoscope combined with tumor maker determination to lung cancer. METHODS: By fibro-optic bronchoscope (FB) and electrochemiluminescence (ECL) examinations, 98 cases with lung cancer and 88 cases with benign lung disease were studied for calculating the detectable sensitivity and specificity to lung cancer, then further for evaluating the clinical value of FB examination combined with detection of tumor marker in serum/pleural fluid of patients with lung cancer. Results In patients with lung cancer, the serum levels of CEA, CA125 and CYFRA21-1 were (46.34 +/- 18.28) ng/mL, (83.34 +/- 33.26) U/mL and (25.67 +/- 10.32) ng/mL respectively, which were higher than those in patients with benign lung diseases. The serum levels of above three tumor markers in patients with lung cancer all were significantly higher than those in patients with benign lung diseases (P < 0.05). In the 36 specimens of pleural fluid, three tumor markers were higher than those in the corresponding serum samples. The detectable sensitivity of each tumor marker in pleural fluid was higher than that in serum. The sensitivity, specificity and overall accuracy of CEA in lung cancer were 37.5%, 87.5% and 63.6% respectively, of CA125 were 67.7%, 40.9% and 54.9%; of CYFRA21-1 were 56.3%, 81.8% and 68.5%; of FB were 60.4%, 100.0% and 79.4% respectively. The sensitivity, specificity or overall accuracy of fibro-optic bronchoscope combined with tumor marker (TM) examination to diagnosis of lung cancer was 90.6%, 92.0% or 91.3% respectively. CONCLUSION: The FB examination is valuable in diagnosing lung cancer, and by combined with TM determination, can further improve the accuracy to diagnosis of lung cancer.